Several groundbreaking medications are revolutionizing diabetes management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as promising options. Retatrutide, a twin GIP and GLP-1 target activator, exhibits remarkable fat reduction coupled with improved glucose regulation. Cagrillintide, another GLP-1 stimulant, is now in cli